Has the problem of thrombosis after immunization with COVID-19 recombinant vector vaccine been overcome?
Central funds will support detailed application procedures for degradable plastics and waste plastics
Has the thrombosis problem after immunization with the COVID-19 recombinant vector vaccine been overcome?
The new crown recombinant protein vaccine developed by the team of Academician Gao Fu officially started vaccination
GSK adjuvant recombinant new crown vaccine enters Phase 3 clinical trials, and the study was postponed due to insufficient immune response
circulating tumor DNA can be used to predict the risk of recurrence of colorectal cancer after surgery
Discover a new canine-feline recombinant coronavirus that can infect humans!
tumor DNA can be used to predict the risk of postoperative recurrence of colorectal cancer
The entry of GSK adjuvant recombinant new crown vaccine into phase 3 clinical trials was delayed due to insufficient immune response
China's research and development of new crown recombinant protein vaccine three-dose program in many places, one after another
GSK adjuvant recombinant new crown vaccine enters Phase 3 clinical trials
Sansheng Guojian Recombinant Anti-IL-17A Humanized Monoclonal Antibody Phase II Clinical Completion of the First Subject Enrolled
Eur J Cancer: Circulating tumor DNA (ctDNA) to identify EGFR-mutated NSCLC who benefited from continuous EGFR-TKI treatment
Br J Cancer: Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA): Prognostic Targets for Metastatic Colorectal Cancer
Recombinant new coronavirus vaccine (CHO cells) is approved for emergency use | Transformation Highlights
The new crown DNA vaccine will start phase 3 clinical Ai Di Weixin has exclusive rights in Greater China
Radiotherapy and Oncology: The influence of DNA repair and reactive oxygen levels on the radiation resistance of pancreatic cancer
DNA replication sequence maintains cell epigenetic state
Recombinant new coronavirus fusion protein vaccine, a subsidiary of Joincare Pharmaceuticals, has been approved for clinical use
China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials